Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 7/20 | 0.56 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.52 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.52 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.51 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.49 |
| ▸ | GRIK1 | P39086 | 4/20 | 0.48 |
| ▸ | DCLRE1B | Q9H816 | 1/20 | 0.47 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.46 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2275722 | 0.90 | ACLY (0.57) | ACLYSUCNR1NPC1RAB9A | |
| SCHEMBL14429486 | 0.86 | KCNMA1 (0.44) | ACLYPTGER4PTGER2SUCNR1KCNMA1 | |
| SCHEMBL2278464 | 0.85 | ACLY (0.49) | ACLYSUCNR1HCAR2NPC1RAB9A | |
| SCHEMBL2269657 | 0.85 | ALDH1A1 (0.45) | ACLYPTGER4PTGER2KCNMA1NPC1 | |
| SCHEMBL27696863 | 0.83 | ACLY (0.62) | ACLYSUCNR1HCAR2GRIK1SERPINE1 | |
| SCHEMBL2276482 | 0.81 | ACLY (0.74) | ACLYSUCNR1GRIK1SERPINE1NPC1 | |
| SCHEMBL2268189 | 0.81 | ACLY (0.61) | ACLYSUCNR1NPC1RAB9A | |
| SCHEMBL2274223 | 0.80 | ALDH1A1 (0.53) | GRIK1NPC1RAB9A | |
| SCHEMBL12117713 | 0.80 | ALDH1A1 (0.50) | ACLYNPC1RAB9A | |
| SCHEMBL4209151 | 0.79 | ACLY (0.55) | ACLYSUCNR1HCAR2GRIK1DCLRE1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7999132-B2 | Anthranilic acid derivative or salt thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2011-08-16 | — | — | US | disclosed |
| US-7999132-B2 | Anthranilic acid derivative or salt thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2011-08-16 | — | — | US | disclosed |
| US-7999132-B2 | Anthranilic acid derivative or salt thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2011-08-16 | — | — | US | disclosed |
| US-20090240052-A1 | NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2009-09-24 | — | — | US | disclosed |
| US-20090240052-A1 | NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2009-09-24 | — | — | US | disclosed |
| US-20090240052-A1 | NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2009-09-24 | — | — | US | disclosed |
| EP-1820795-A1 | NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2007-08-22 | — | — | EP | disclosed |
| EP-1820795-A1 | NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2007-08-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090240052-A1 | NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | MMP13, MMP26, MMP11 | ACLY 653/4885PTGER4 1114/4885PTGER2 2309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.